Caliway Biopharmaceuticals Co. L
6919
Rangering i aksjer
#4343
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Aksjekurs
$2.29
Markedsverdi
$3.56B
Endring (1 dag)
-2.50%
Endring (1 år)
-57.22%
Land
TW
Handel Caliway Biopharmaceuticals Co. L (6919)
Kategori
Healthcare
EPS for Caliway Biopharmaceuticals Co. L (6919)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Caliway Biopharmaceuticals Co. L er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Caliway Biopharmaceuticals Co. L fra 2019 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2025 | $-0.01 | -41.60% |
| 2024 | $-0.01 | -1.57% |
| 2023 | $-0.01 | 62.82% |
| 2022 | $-0.01 | -10.34% |
| 2021 | $-0.01 | 89.13% |
| 2020 | 0.00 | -19.30% |
| 2019 | $-0.01 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| - | - |
CH
|
